-
EP2994131
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2994131
| EP2994131 - LOW DOSE PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 17.05.2019 Database last updated on 11.04.2026 | |
| Former | Examination is in progress Status updated on 10.02.2017 | Most recent event Tooltip | 17.05.2019 | Application deemed to be withdrawn | published on 19.06.2019 [2019/25] | Applicant(s) | For all designated states Cipla Limited Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel Mumbai 400 013 / IN | [2016/11] | Inventor(s) | 01 /
MALHOTRA, Geena 4 Anderson House Opposite Mazgaon Post Office Mazgaon Maharashtra Mumbai 400 010 / IN | 02 /
PURANDARE, Shrinivas Madhukar B/25 Naperol Towers Opposite R.A. Kidwai Road Opposite Gyaneshwar Vidyalaya Wadala Maharashtra Mumbai 400 031 / IN | [2016/11] | Representative(s) | Privett, Marianne Alice Louise Venner Shipley LLP 200 Aldersgate London EC1A 4HD / GB | [N/P] |
| Former [2016/11] | Privett, Marianne Alice Louise A.A. Thornton & Co. 10 Old Bailey London EC4M 7NG / GB | Application number, filing date | 14731760.6 | 08.05.2014 | [2016/11] | WO2014GB51400 | Priority number, date | INMM16962013 | 10.05.2013 Original published format: IN MM16962013 | [2016/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014181108 | Date: | 13.11.2014 | Language: | EN | [2014/46] | Type: | A1 Application with search report | No.: | EP2994131 | Date: | 16.03.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.11.2014 takes the place of the publication of the European patent application. | [2016/11] | Search report(s) | International search report - published on: | EP | 13.11.2014 | Classification | IPC: | A61K31/41, A61P7/00 | [2016/11] | CPC: |
A61K31/4196 (EP,US);
A61K31/4412 (EP,US);
A61K9/0053 (US);
A61K9/0056 (EP,US);
A61K9/0095 (EP,US);
A61K9/1075 (EP,US);
A61K9/14 (US);
A61K9/1635 (EP,US);
A61K9/1641 (EP,US);
A61K9/1652 (EP,US);
A61K9/20 (US);
A61K9/2009 (EP,US);
A61K9/2054 (EP,US);
A61K9/2095 (EP,US);
A61K9/28 (US);
A61K9/4808 (US);
A61K9/4825 (US);
A61K9/4858 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/11] | Extension states | BA | 21.01.2016 | ME | 21.01.2016 | Title | German: | NIEDRIGDOSIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNG | [2016/11] | English: | LOW DOSE PHARMACEUTICAL COMPOSITION | [2016/11] | French: | COMPOSITION PHARMACEUTIQUE À FAIBLE DOSAGE | [2016/11] | Entry into regional phase | 01.12.2015 | National basic fee paid | 01.12.2015 | Designation fee(s) paid | 01.12.2015 | Examination fee paid | Examination procedure | 01.12.2015 | Examination requested [2016/11] | 21.07.2016 | Amendment by applicant (claims and/or description) | 09.02.2017 | Despatch of a communication from the examining division (Time limit: M04) | 19.06.2017 | Reply to a communication from the examining division | 20.07.2017 | Observations by third parties | 13.11.2017 | Despatch of a communication from the examining division (Time limit: M04) | 23.03.2018 | Reply to a communication from the examining division | 20.07.2018 | Observations by third parties | 06.09.2018 | Despatch of a communication from the examining division (Time limit: M04) | 17.01.2019 | Application deemed to be withdrawn, date of legal effect [2019/25] | 08.02.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/25] | Fees paid | Renewal fee | 25.05.2016 | Renewal fee patent year 03 | 10.05.2017 | Renewal fee patent year 04 | 11.05.2018 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I] PORTER: "DEFERASIROX, an effective once daily orally active iron chelator", DRUGS OF TODAY, vol. 42, no. 10, 2006 - 2006, pages 623 - 637, XP002727510 [I] 1-23 * page 627; table II * DOI: http://dx.doi.org/10.1358/dot.2006.42.10.1009901 | [I] GARADAH ET AL: "The impact of two different doses of chelating therapy (deferasirox9 on echocardiographic tissue Doppler indices in patients with thalassemia major", EUR.J.HAEMATOLOGY, vol. 87, 2011 - 2011, pages 267 - 273, XP002727511 [I] 1-23 * page 268 * DOI: http://dx.doi.org/10.1111/j.1600-0609.2011.01641.x | [I] COHEN ET AL: "Effect of transfusional iron intake on response to chelation therapy in beta thalassemia major", BLOOD, vol. 111, 2008 - 2008, pages 583 - 587, XP002727512 [I] 1-23 * table 1 * DOI: http://dx.doi.org/10.1182/blood-2007-08-109306 | [X] RENZO GALANELLO ET AL: "Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major", HAEMATOLOGICA, vol. 91, no. 10, 1 October 2006 (2006-10-01), Italy, pages 1343 - 1351, XP055130708, ISSN: 1592-8721 [X] 1-23 * Study design * | by applicant | NAEEM ASLAM; PARVEEN METTU; LUIS S. MARSANO-OBANDO; ANTHONY MARTIN, JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, vol. 20, no. 8, 2010, pages 551 - 553 [I] 1-23 * table 1 * | NEPHROL. DIAL. TRANSPLANT, vol. 23, no. 10, 2008, pages 3356 - 3358 [X] 1-23 * Study design * | DUBOURG L; LAURAIN C; RANCHIN B; PONDARRE C; HADJ-AISSA A; SIGAUDO-ROUSSEL D; COCHAT P, PEDIATRIC NEPHROLOGY, vol. 27, no. 11, November 2012 (2012-11-01), pages 2115 - 22 | STEVEN GRANGE; DOMINIQUE M. BERTRAND; DOMINIQUE GUERROT; FLORENCE EAS; MICHEL GODIN, NEPHROL. DIAL. TRANSPLANT, vol. 25, no. 7, 2010, pages 2376 - 2378 | F. DAHOOEE BALOOCH, BIOMETALS, vol. 27, 2014, pages 89 - 95 |